'On standalone basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of RPG Life Sciences has increased 2.12% to Rs 168.92 crore. Operating profit margin has declined from 23.62% to 21%, leading to 9.21% decline in operating profit to Rs 35.47 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 19.31% to 18.41%. Purchase of finished goods cost rose from 14.84% to 19.00%. Employee cost decreased from 19.53% to 19.37%. Other expenses fell from 23.02% to 22.83%.
Other income up 120.68% to Rs 5.23 crore. PBIDT fell 1.79% to Rs 40.7 crore. Provision for interest fell 13.33% to Rs 0.13 crore.
PBDT fell 1.74% to Rs 40.57 crore. Provision for depreciation down 2.84% to Rs 5.14 crore.
Profit before tax down 1.58% to Rs 35.43 cror...
Pleaselogin & subscribe to view the full report.
More Reports
|
|